Magacizumab

N/A

Report date: 2025/12/31 13:42:31

Base Information

Drug NameMagacizumab
Drug Alias NameMagaFabSTX-001STX001STX-001(Senya Therapeutics)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionAnti-Leucine-rich alpha-2-glycoprotein
TargetsLeucine-rich alpha-2-glycoprotein
Therapy Area/IndicationsRenal Insufficiency, ChronicMacular Degeneration
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited Kingdom
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesUniversity College LondonSenya Therapeutics
China Registration ClassN/A

Develop Information

Active CompaniesSenya TherapeuticsUniversity College London
Inactive CompaniesN/A
Active IndicationsRenal Insufficiency, ChronicMacular Degeneration
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A